Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) (vol 20, pg 614, 1997)

被引：0

|

作者：

Pyorala, K

Pedersen, TR

Kjekshus, J

Faergeman, O

Olsson, AG

Thorgeirsson, G

机构：

来源：

DIABETES CARE | 1997年 / 20卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1048 / 1048

页数：1

相关论文

共 38 条

[21] Extended follow-up of patients in the Scandinavian Simvastatin Survival Study (4S) shows increased survival benefit of simvastatin therapy
Pedersen, TR
Wilhelmsen, L
Faergeman, O
Strandberg, T
Thorgeirsson, G
Troedsson, L
Kristianson, J
Cook, TJ
Kjekshus, J
CIRCULATION, 1998, 98 (17) : 451 - 451
[22] THE EFFECT OF CHOLESTEROL-LOWERING WITH SIMVASTATIN ON CORONARY EVENTS IN DIABETIC-PATIENTS WITH CORONARY HEART-DISEASE
PYORALA, K
PEDERSEN, TR
KJEKSHUS, J
DIABETES, 1995, 44 : A35 - A35
[23] Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris - Findings from the Scandinavian Simvastatin Survival Study (4S)
Miettinen, TA
Pyorala, K
Olsson, AG
Musliner, TA
Cook, TJ
Faergeman, O
Berg, K
Pedersen, T
Kjekshus, J
CIRCULATION, 1997, 96 (12) : 4211 - 4218
[24] Cholesterol lowering and the use of healthcare resources: Results of the Scandinavian Simvastatin survival study (vol 93, pg 1796, 1996)
Pedersen
CIRCULATION, 1996, 94 (04) : 849 - 849
[25] BASE-LINE SERUM-CHOLESTEROL AND TREATMENT EFFECT IN THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S)
PEDERSEN, TR
KJEKSHUS, J
BERG, K
HAGHFELT, T
FAERGEMAN, O
THORGEIRSSON, G
PYORALA, K
MIETTINEN, T
WILHELMSEN, L
OLSSON, AG
WEDEL, H
LANCET, 1995, 345 (8960): : 1274 - 1275
[26] Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients (vol 4, pg 272, 2010)
Averna, Maurizio
JOURNAL OF CLINICAL LIPIDOLOGY, 2011, 5 (05) : 418 - 418
[27] Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S) -: Impact of predicted risk on the benefit of cholesterol-lowering treatment
Wilhelmsen, L
Pyörälä, K
Wedel, H
Cook, T
Pedersen, T
Kjekshus, J
EUROPEAN HEART JOURNAL, 2001, 22 (13) : 1119 - 1127
[28] Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). (Reprinted from Circulation, vol 97, pg 1453-60, 1998)
Pedersen, TR
Olsson, AG
Færgerman, O
Kjekshus, J
Wedel, H
Berg, K
Wilhelmsen, L
Haghfelt, T
Thorgeirsson, G
Pyörälä, K
Miettinen, T
Christophersen, B
Tobert, JA
Musliner, TA
Cook, TJ
ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (03) : 99 - 106
[29] Cost effectiveness of LDL-C reduction in diabetic CHD patients: Implications from the Scandinavian Simvastatin Survival Study (4S)
Schwartz, JS
Broccuzzi, SJ
Glick, H
Cook, JR
Kinosian, B
Davis, L
Pedersen, TR
Kjekshus, J
CIRCULATION, 1997, 96 (08) : 2827 - 2827
[30] LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH CORONARY HEART-DISEASE - THE 4S TRIAL SHOWED THAT LOWERING HIGH CHOLESTEROL LEVELS IMPROVES SURVIVAL IN PATIENTS WITH CORONARY HEART-DISEASE - DO THE BENEFITS EXTEND TO THOSE WITH AVERAGE CHOLESTEROL LEVELS
AYLWARD, P
COLQUHOUN, D
GLASZIOU, P
HARRIS, P
HUNT, D
KEECH, A
MACMAHON, S
SHARPE, N
SIMES, J
THOMPSON, P
THOMSON, A
TONKIN, A
WEST, M
WHITE, H
MEDICAL JOURNAL OF AUSTRALIA, 1995, 162 (09) : 455 - 456

← 1 2 3 4 →